Daidzein and Equol: Ex Vivo and In Silico Approaches Targeting COX-2, iNOS, and the Canonical Inflammasome Signaling Pathway.
Yazmín Karina Márquez-FloresElizdath Martínez-GaleroJosé Correa-BasurtoYudibeth Sixto-LópezIsabel VillegasMaría Á RosilloAna CárdenoCatalina Alarcón-de-la-LastraPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
generation, as well as the inhibition of the canonical inflammasome pathway, regulating NLRP3, and consequently decreasing IL-1β and IL-18 activation.